10-QPeriod: Q1 FY2019

DEXCOM INC Quarterly Report for Q1 Ended Mar 31, 2019

Filed May 1, 2019For Securities:DXCM

Summary

DexCom, Inc. (DXCM) reported its first quarter 2019 financial results, showcasing significant revenue growth year-over-year, though the company continues to operate at a net loss. Total revenues surged by 52% to $280.5 million, driven by strong sales volume of both disposable sensors and durable systems, indicating continued expansion of its customer base globally. Despite the impressive top-line performance, the company's gross margin saw a slight decrease to 60% from 64% in the prior year's quarter, attributed to evolving channel strategies, product mix, and investments in infrastructure for production capacity expansion. Operating expenses also increased, particularly in Research & Development and Selling, General & Administrative areas, contributing to a wider operating loss of $14.4 million. The net loss for the quarter was $26.9 million, or $(0.30) per share. The company maintains a strong liquidity position with over $1.3 billion in cash, cash equivalents, and marketable securities, providing confidence in its ability to fund operations for at least the next 12 months.

Financial Statements
Beta

Key Highlights

  • 1Revenue increased by 52% year-over-year to $280.5 million, driven by higher sales volume of CGM systems and sensors.
  • 2Gross profit grew to $168.8 million, but the gross margin percentage decreased to 60% from 64% in the prior year period.
  • 3Operating loss widened to $14.4 million, compared to $30.7 million in Q1 2018, due to increased R&D and SG&A expenses.
  • 4Net loss for the quarter was $26.9 million, or $(0.30) per diluted share, a slight increase from the previous year's net loss of $24.2 million.
  • 5Cash, cash equivalents, and marketable securities totaled $1.358 billion as of March 31, 2019, indicating a strong liquidity position.
  • 6The company adopted new lease accounting standards (ASC 842) in Q1 2019, resulting in the recognition of operating lease right-of-use assets and liabilities on the balance sheet.
  • 7A restructuring plan was announced in February 2019 to transition certain operations to the Philippines, expected to incur approximately $9 million in pre-tax charges primarily in the first half of 2019.

Frequently Asked Questions

DexCom's revenue growth of 52% to $280.5 million in Q1 2019 was primarily driven by an increase in sales volume for both its disposable sensors and durable continuous glucose monitoring (CGM) systems. This reflects the continued expansion of its customer base, both domestically and internationally.

The decrease in gross margin percentage to 60% in Q1 2019 from 64% in Q1 2018 is attributed to several factors. These include changes in the company's channel strategy, product mix evolution, and investments made to scale infrastructure and expand production capacity. Higher freight and warranty costs also contributed to the margin compression.

DexCom maintains a strong liquidity position, with cash, cash equivalents, and short-term marketable securities totaling approximately $1.358 billion as of March 31, 2019. The company believes these funds, along with projected cash from operations and its revolving credit facility, will be sufficient to meet its liquidity requirements for at least the next 12 months.

DexCom adopted ASC 842 (Leases) in Q1 2019 using a modified retrospective transition. This resulted in the recognition of operating lease right-of-use assets and liabilities on the balance sheet, totaling $26.7 million and $40.4 million respectively at the adoption date. There was a $2.1 million cumulative-effect adjustment to retained earnings and no material impact on the statement of operations for the quarter.